# State Institute for Drug Control

CERTIFICATE NUMBER: sukls72897/2019

## CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER

#### Part 1

Issued following an inspection in accordance with:

Art. 111(5) of Directive 2001/83/EC as amended

The competent authority of Czech Republic confirms the following:

The manufacturer: Contipro, a.s.

Site address: Dolní Dobrouč 401, Dolní Dobrouč, 561 02, Czech Republic

Is an active substance manufacturer that has been inspected in accordance with Art. 111(1) of Directive 2001/83/EC transposed in the following national legislation:

Section 101 paragraph 3 of the Act No 378/2007 Coll., on Pharmaceuticals and on Amendments to Some Related Acts, as amended

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on **2019-04-25**, it is considered that it complies with:

• The principles of GMP for active substances <sup>3</sup> referred to in Article 47 of Directive 2001/83/EC.

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. This certificate is valid only when presented with all pages and both Parts 1 and 2. The authenticity of this certificate may be verified in EudraGMDP. If it does not appear, please contact the issuing authority.

Online EudraGMDP, Ref key: 55769 Issuance Date: 2019-07-15 Signatory: Confidential Page 1 of 2

<sup>&</sup>lt;sup>1</sup> The certificate referred to in paragraph 111(5) of Directive 2001/83/EC and 80(5) of Directive 2001/82/EC, shall also be required for imports coming from third countries into a Member State.

<sup>&</sup>lt;sup>2</sup> Guidance on the interpretation of this template can be found in the Help menu of EudraGMDP database.

<sup>&</sup>lt;sup>3</sup> These requirements fulfil the GMP recommendations of WHO.

### Part 2

Manufacture of active substance. Names of substances subject to inspection:

SODIUM HYALURONATE CAS 9067-32-7 (2 MANUFACTURING PROCESSES)(en)

### 3. MANUFACTURING OPERATIONS - ACTIVE SUBSTANCES

Active Substance: SODIUM HYALURONATE CAS 9067-32-7 (2 MANUFACTURING PROCESSES)

Manufacturing of Active Substance using Biological Processes
3.3.1 Fermentation
3.3.2 Cell Culture :
(bacterial)
3.3.3 Isolation / Purification
3.3.5 Other:
(acidic hydrolysis during second manufacturing process)
General Finishing Steps
3.5.1 Physical processing steps :
(drying, sieving, molecular weight decreasing)
3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material
which is in direct contact with the substance)
3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging
material or container. This also includes any labelling of the material which could be used for
identification or traceability (lot numbering) of the active substance)
Quality Control Testing
3.6.1 Physical / Chemical testing
3.6.2 Microbiological testing excluding sterility testing

2019-07-15

Name and signature of the authorised person of the Competent Authority of Czech Republic

Confidential Státní ústav pro kontrolu léčiv Tel: Confidential

Fax: Confidential

Online EudraGMDP, Ref key: 55769 Issuance Date: 2019-07-15 Signatory: Confidential Page 2 of